Amphastar Pharma (AMPH) Tops Q3 EPS by 45c

Amphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $1.15, $0.45 better than the analyst estimate of $0.70. Revenue for the quarter came in at $180.6 million versus the consensus estimate of $174.63 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Citi lowers East West Bancorp price target to $152
• Bernstein on Otis Worldwide Corp (OTIS) CEO transition: 'Investors we’ve spoken with have been largely cautious on the news'